β2 microglobulin levels and high sensitive C-reactive protein as markers of histological activity in patients with chronic idiopathic ulcerative colitis;Niveles de β2 microglobulina y proteína C reactiva ultrasensible como marcadores de actividad histológica en pacientes con colitis ulcerativa crónica idiopática

Gaceta Medica de Mexico

Volumn 146, Issue 1, 2010, Pages 31-35

  Yamamoto Furusho, Jesús K ^a   Camacho Escobedo, Jesús ^a   Téllez Ávila, Félix ^a   Barreto, Rafael ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

B2 microglobulin; C reactive protein; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENDOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; ULCERATIVE COLITIS; BLOOD; MALE; PATHOLOGY;

ADULT; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE;

EID: 77954273759     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Baumgart DC, Sandborn W. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657. (Pubitemid 46722637)
2. Lichstenstein G, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute. Technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987.
3. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-255. (Pubitemid 46115394)
4. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712
5. D'Haens G, Sandborn WJ, Feagan BG. A Review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-786. (Pubitemid 46306135)
6. Zissis M, Afroudakis A, Galanopoulos G, Palermos L, Boura X, Michopoulos S, et al. B2 Microglobulin: Is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol 2001;96:2177-2183.
7. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964;1:89-92.
8. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29;669-674.
9. Mazlam M, Hodgson H. Interrelations between interleukin-6, interleukin-1beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35:77-83. (Pubitemid 2018714)
10. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982 27:533-537. (Pubitemid 12120288)
11. Ahmadi AA, Polyak S. Endoscopy/surveillance in inflammatory bowel disease. Surg Clin N Am 2007;87:743-762.
12. Kiesslich R, Galle PR, Neurath MF. Endoscopic surveillance in ulcerative colitis: smart biopsies do it better. Gastroenterology 2007;133:742-745. (Pubitemid 47374156)
13. Rodgers AD, Cummins AG. CRP Correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007;52:2063-2068. (Pubitemid 47246515)
14. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Non-invasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-169.
15. Lok KH, Ng CH, Hung HG, Li KF, Li KK, Szeto ML. Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients. J Dig Dis 2008;9:219-224.
16. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712.
17. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B; IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57:1518-1523.